Leyden Labs provides a platform that targets commonalities of viral families to protect humanity from known and future viruses.
Leyden Labs has raised €322M across 6 funding rounds from 16 investors, most recently a round in Jun 2026. Based in Amsterdam, Netherlands; founded 2020; active in Healthtech. Data as of 7 Aug 2026.
Timing: too soon vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-06-25 | Other | €40M | ClavystBio,European Innovation Council (EIC) Fund,Gates Foundation Strategic Investment Fund,Invest-NL,Other investors | View deal → |
| 2025-10-03 | Other | €30M | European Innovation Council (EIC) Fund,Invest-NL | View deal → |
| 2025-06-04 | Debt | €20M | European Investment Bank (EIB) | View deal → |
| 2025-01-10 | Other | €68M | Casdin Capital,ClavystBio,GV (Google Ventures),Polaris Partners,Qiming Venture Partners | View deal → |
| 2022-01-25 | Series B | €124M | Bluebird Ventures,Byers Capital,Casdin Capital,F-Prime Capital,GV,Invus+1 more | View deal → |
| 2021-03-25 | Series A | €40M | GV | View deal → |
